Naphthyl bradykinin receptor antagonists

A method for the treatment or prevention of a physiological disorder associated with an excess of bradykinins in which a bradykinin receptor is inhibited, which method comprises administering to a mammal in need of said treatment an effective amount of a compound of the formula ##STR15## wherein:

• R.sup.2 is hydrogen, hydroxy, or C.sub.1 -C.sub.6 alkoxy;
• the dotted line represents an optional covalent bond;
• Y is hydroxy, or ##STR16## where Y.sup.a is a bond, --CH.sub.2, or --CH.sub.2 CH.sub.2 --;
• and
• R.sup.1 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, or hydroxy;
• R.sup.3 is aryloxy, C.sub.1 -C.sub.6 alkoxy, hydroxy or
• -Q-(CH.sub.2).sub.n --NR.sup.a R.sup.b
• where,
• Q is --O-- or --CH.sub.2,
• n is 1-6,
• R.sup.a and R.sup.b are independently hydrogen or C.sub.1 -C.sub.6 alkyl or are taken together with the nitrogen to which they are bonded to constitute a heterocyclic ring selected from the group consisting of pyrrolidinyl, piperazinyl, piperidinyl, hexamethyleneiminyl, 4-methylpiperidinyl, imidazolinyl, heptamethyleneiminyl, morpholinyl, and N-methylpyrrolidinyl;
• or a pharmaceutically acceptable salt or solvate thereof.